Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Soodabeh Shahid Sales

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

S. Shahid Sales1, M. Mehramiz2, S.A. Aledavood3, M. Joudi Mashhad1, S. Ahmadi Simab3, A. Avan4

Author affiliations

  • 1 Clinical Oncology, Cancer Research Center, Mashhad University of Medical Sciences, 9176613775 - Mashhad/IR
  • 2 Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, 9176613775 - Mashhad/IR
  • 3 Cancer Research Center, Mashhad University of Medical Sciences, 9176613775 - Mashhad/IR
  • 4 Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, 051 - Mashhad/IR
More

Resources

Abstract 5057

Background

Breast cancer is second leading cause of cancer-related-deaths in women, supporting the need for the detection of novel prognostic biomarkers for risk stratification. There is growing body of evidence showing the association of common genetic variants on chromosome 9p21 with an increased risk of developing different tumors and metabolic disorders. Here we investigated the association of a genetic variant in CDKN2A/B, rs1333049, for the first time in 303 subjects with and without breast cancer.

Methods

Method: Genotyping was carried out using TaqMan real time PCR method in case and control groups. The associations of this genetic variant were evaluated with breast cancer risk and pathological information of patients.

Results

We observed that the minor allele homozygote situation of this genetic variant in total population was 10%, while this condition in heterozygote was 38%. the logistic regression under recessive genetic model revealed that breast cancer patients with GG genotype had higher risk of breast cancer, compared to CC/CG genotypes (e.g., OR = 2.8, 95% CI:1.4-5.4, p = 0.001), after adjusted for age, and BMI.

Conclusions

We demonstrated that patients carrying the GG genotype for CDKN2A/B rs1333049 polymorphism had an increased risk of breast cancer susceptibility, indicating further studies in a larger and prospective setting to show the value of emerging marker as a risk stratification biomarker in breast cancer.

Clinical trial identification

Legal entity responsible for the study

Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

Mashhad University of Medical Sciences, Mashhad, Iran.

Editorial Acknowledgement

Mashhad University of Medical Sciences, Mashhad, Iran.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings